VV-14300 for the Treatment of Type 1 Diabetes

Study acronym: RELIEVE
StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date pushed from Sep 2026 to Oct 2026
    • Site details revised at 2 of 2 sites
  2. Re-verified, no change to tracked fields
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is testing VV-14300 in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system. VV-14300 is an investigational gene therapy that is injected into muscle and is designed to help remove excess sugar from the blood.
Trial Details
NCT Number NCT07831798
Lead Sponsor Kriya Therapeutics, Inc.
Conditions
(from sponsor)		 Type 1 Diabetes Mellitus
Related terms Diabetes Mellitus, Type 1
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov